Cost-Effectiveness of Treating Esophageal Varices

Clinics in Liver Disease

Volumn 10, Issue 3, 2006, Pages 679-689

  Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE 5 NITRATE; NADOLOL; NITRATE; PROPRANOLOL; SCLEROSING AGENT;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; ECONOMIC EVALUATION; ENDOSCOPIC SURGERY; ENDOSCOPIC VARICEAL LIGATION; ENDOSCOPY; ESOPHAGUS VARICES; HEALTH CARE COST; HEMODYNAMIC MONITORING; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LIVER CIRRHOSIS; MORTALITY; PORTOSYSTEMIC ANASTOMOSIS; PRACTICE GUIDELINE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCLEROTHERAPY; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; COST-BENEFIT ANALYSIS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 33845341396     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.11.001     Document Type: Review

References (27)

1. McCormick P.A., and O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut 49 (2001) 682-685
2. D'Amico G., Pagliaro L., and Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19 (1999) 475-505
3. Imperiale T.F., and Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 33 (2001) 802-807
4. Talwalkar J.A., and Kamath P.S. An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis. Am J Med 116 (2004) 759-766
5. Drummond M. The role of health economics in clinical evaluation. J Eval Clin Pract 1 (1995) 71-75
6. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276 (1996) 1253-1258
7. Sonnenberg F., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 13 (1993) 322-338
8. Teran J.C., Imperiale T.F., Mullen K.D., et al. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology 112 (1997) 473-482
9. Arguedas M.R., Heudebert G.R., Eloubeidi M.A., et al. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol 97 (2002) 2441-2452
10. Grace N. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 92 (1997) 1081-1091
11. Grace N.D., Groszmann R.J., Garcia-Tsao G., et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 28 (1998) 868-880
12. Jalan R., and Hayes P.C. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 46 Suppl 3-4 (2000) III1-III15
13. Saab S., DeRosa V., Nieto J., et al. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol 98 (2003) 763-770
14. Spiegel B.M., Targownik L., Dulai G.S., et al. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective?. Hepatology 37 (2003) 366-377
15. Groszmann R.J., and Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 39 (2004) 280-282
16. Imperiale T.F., Chalasani N., and Klein R.W. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis. Am J Gastroenterol 98 (2003) 2742-2750
17. Hicken B.L., Sharara A.I., Abrams G.A., et al. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Aliment Pharmacol Ther 17 (2003) 145-153
18. Russo M.W., Zacks S.L., Sandler R.S., et al. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology 31 (2000) 358-363
19. Rubenstein J.H., Eisen G.M., and Inadomi J.M. A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol 99 (2004) 1274-1288
20. Raines D.L., Dupont A.W., and Arguedas M.R. Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding. Aliment Pharmacol Ther 19 (2004) 571-581
21. Targownik L.E., Spiegel B.M., Dulai G.S., et al. The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. Am J Gastroenterol 99 (2004) 1306-1315
22. Rubenstein J.H., and Inadomi J.M. Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable?. Hepatology 37 (2003) 249-252
23. Siegel J.E., Weinstein M.C., Russell L.B., et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276 (1996) 1339-1341
24. Earle C.C., Chapman R.H., Baker C.S., et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18 (2000) 3302-3317
25. Stone P.W., Schackman B.R., Neukermans C.P., et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis 5 (2005) 383-391
26. Brauer C.A., Rosen A.B., Olchanski N.V., et al. Cost-utility analyses in orthopaedic surgery. J Bone Joint Surg Am 87 (2005) 1253-1259
27. Neumann P.J., Stone P.W., Chapman R.H., et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 132 (2000) 964-972